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Dysferlin Mediates the Cytoprotective Effects of TRAF2 Following
Myocardial Ischemia Reperfusion Injury
Huei-Ping Tzeng, PhD; Sarah Evans, PhD; Feng Gao, MD; Kari Chambers, PhD; Veli K. Topkara, MD; Natarajan Sivasubramanian, PhD;
Philip M. Barger, MD; Douglas L. Mann, MD
Background-—We have demonstrated that tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2), a scaffolding protein
common to TNF receptors 1 and 2, confers cytoprotection in the heart. However, the mechanisms for the cytoprotective effects of
TRAF2 are not known.
Methods/Results-—Mice with cardiac-restricted overexpression of low levels of TRAF2 (MHC-TRAF2LC) and a dominant negative
TRAF2 (MHC-TRAF2DN) were subjected to ischemia (30-minute) reperfusion (60-minute) injury (I/R), using a Langendorff
apparatus. MHC-TRAF2LC mice were protected against I/R injury as shown by a signiﬁcant 27% greater left ventricular (LV)
developed pressure after I/R, whereas mice with impaired TRAF2 signaling had a signiﬁcantly 38% lower LV developed pressure,
a 41% greater creatine kinase (CK) release, and 52% greater Evans blue dye uptake after I/R, compared to LM. Transcriptional
proﬁling of MHC-TRAF2LC and MHC-TRAF2DN mice identiﬁed a calcium-triggered exocytotic membrane repair protein, dysferlin, as
a potential cytoprotective gene responsible for the cytoprotective effects of TRAF2. Mice lacking dysferlin had a signiﬁcant 39%
lower LV developed pressure, a 20% greater CK release, and 29% greater Evans blue dye uptake after I/R, compared to wild-
type mice, thus phenocopying the response to tissue injury in the MHC-TRAF2DN mice. Moreover, breeding MHC-TRAF2LC onto a
dysferlin-null background signiﬁcantly attenuated the cytoprotective effects of TRAF2 after I/R injury.
Conclusion-—The study shows that dysferlin, a calcium-triggered exocytotic membrane repair protein, is required for the
cytoprotective effects of TRAF2-mediated signaling after I/R injury. ( J Am Heart Assoc. 2014;3:e000662 doi: 10.1161/
JAHA.113.000662)
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M yocardial reperfusion after a period of ischemia may beregarded as a “mixed blessing.” That is, on the one
hand, there is the clear-cut beneﬁt that occurs as the result of
recovery of heart muscle that attends reperfusion; however, on
the other hand, there are also deleterious reperfusion-depen-
dent effects that can be attributed to excessive activation of
proinﬂammatory cytokines. Although excessive activation of
proinﬂammatory cytokines may be overtly deleterious by
producing left ventricular (LV) dysfunction and increased
tissue destruction attributable to robust inﬂammatory
response, there is increasing evidence that activation of
proinﬂammatory cytokines may be beneﬁcial by upregulating
cytoprotective pathways, as well as by promoting tissue repair.
Indeed, we and others have suggested that proinﬂammatory
cytokines belonging to a phylogenetically conserved host
defense system, collectively referred to as innate immunity,
may be beneﬁcial by upregulating cytoprotective pathways, as
well as by promoting tissue repair.1–4 Both gain- and loss-of-
function studies have suggested an important role for tumor
necrosis factor (TNF) with respect to mediating myocardial
cytoprotection in vitro,5 ex vivo,2,4,6,7 as well as in vivo.8–10
Moreover, TNF has been implicated as a mediator of classic
ischemic preconditioning, through a signal transducer and
activator of transcription 3–dependent pathway (SAFE path-
way).4 We have shown, through a variety of experimental
approaches, that signaling through the type 1 (TNFR1) and
type 2 (TNFR2) TNF receptors is sufﬁcient to mimic the effects
of TNF in vitro and ex vivo.5,11 Although it is conceivable that
TNFR1 and TNFR2 activate disparate cytoprotective signal
transduction pathways, the most parsimonious explanation is
that TNFR1 and TNFR2 transduce a common cytoprotective
repertoire in the heart. Noting that the intracellular scaffolding
protein, TNFR-associated factor 2 (TRAF2) was common to
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both TNFR1 and TNFR2, and recognizing that TRAF2 mediates
cytoprotection in nonmyocyte cell types,12 we reasoned that
the cytoprotective effects of TNF in the heart were mediated,
at least in part, through TRAF2. To this end, we generated lines
of mice with low levels of TRAF2 expression in the heart (MHC-
TRAF2LC) and demonstrated that these mice had signiﬁcantly
improved LV functional recovery and signiﬁcantly less LV
tissue injury after ischemia-reperfusion (I/R) injury, when
compared to littermate (LM) control mice.11
To extend our initial observations with respect to the
cytoprotective role of TRAF2 in the heart, here we generate
lines of mice with a cardiac-restricted dominant negative form
of TRAF2 (MHC-TRAF2DN). Notably, hearts from MHC-
TRAF2DN mice demonstrated an I/R injury-induced phenotype
that was opposite to the MHC-TRAF2LC mice, namely,
increased membrane permeability, increased creatine kinase
(CK) release, and signiﬁcantly worse LV functional recovery
after reperfusion. Transcriptional proﬁling of MHC-TRAF2LC
and MHC-TRAF2DN mice and subsequent functional studies in
mice identiﬁed dysferlin, a calcium-triggered exocytotic
membrane repair protein, as a novel cytoprotective gene that
mediates the cytoprotective effects of TRAF2-mediated sig-
naling in the mammalian heart.
Methods
Generation and Characterization of Transgenic
and Knockout Mice
MHC-TRAF2DN Transgenic Mice
Mice with cardiac-restricted expression of dominant negative
TRAF2 (MHC-TRAF2DN) were generated using a dominant
negative TRAF2 construct (a generous gift from Dr Yongwon
Choi13), in which the N-terminal domain of TRAF2 (TRAF2241-
501) lacking the N-terminal ring and zinc ﬁngers essential for
TRAF2-mediated nuclear factor kappa B (NF-jB)- and c-Jun N-
terminal kinase (JNK)-mediated signaling was deleted. Brieﬂy,
the TRAF2D241-501 mutant construct was inserted behind the
myosin heavy chain (aMHC) promoter, which was obtained
from Dr Jeff Robbins. The TRAF2DN transgene constructs were
injected into single-cell embryos of Friend virus B (FVB) mice
at the Transgenic Core Facility at Baylor College of Medicine,
as previously described.11 Founder lines were identiﬁed by
Southern blotting, as described above.11 Age-matched LM
mice that lacked the transgene were used as appropriate
controls. Hemizygous MHC-TRAF2DN mouse lines were
characterized at 12 weeks of age using standard morpholog-
ical and histological analyses, as well as two-dimensional
(2D)-targeted M-mode echocardiography (Echo), as previously
described.11 Further characterization of MHC-TRAF2DN mice
was performed by examining activation of NF-jB in nuclear
extracts obtained from hearts of 12-week na€ıve MHC-
TRAF2DN and LM control mice. Electrophoretic mobility shift
assays (EMSAs) were performed, as previously described,11
using an NF-jB oligonucleotide consensus sequence (50-AGT
TGA GGG GAC TTT CCC AGG C-30; Santa Cruz Biotechnology,
Santa Cruz, CA). Speciﬁcity of binding was determined by
competition with a 209 molar excess of the respective
unlabeled oligonucleotide. JNK activation was determined in
LM control and MHC-TRAF2DN hearts at 12 weeks of age by
Western blot analysis, using rabbit anti-JNK (Catalog No.
9252; Cell Signaling Technology, Danvers, MA) and rabbit
anti-phospho-JNK antibody (Catalog No. 9251 from Cell
Signaling Technology).
MHC-TRAF2LC Transgenic Mice
The hemizygous line of transgenic (Tg) mice with cardiac-
restricted overexpression of low levels of TRAF2 (referred to
as MHC-TRAF2LC) have been described elsewhere in detail
(FVB background).11 Brieﬂy, MHC-TRAF2LC hearts have
improved LV functional recovery, decreased myocardial CK
release, and decreased uptake of Evans blue dye after I/R
injury ex vivo, when compared to LM controls.11
Dysferlin-Null Mice
Dysferlin-null mice (129-Dysftm1Kcam/J [dysferlin/]),14 main-
tained on a 129 background, were purchased from The
Jackson Laboratory (dysferlin/; Stock No. 006830; Bar
Harbor, ME). The lines of 129S1/SvImJ (129) wild-type (WT)
mice that were used as the appropriate controls (http://
jaxmice.jax.org/strain/002448.html) were also purchased
from The Jackson Laboratory (129; Stock No. 0024480).
Dysferlin/ mice were characterized at 12 weeks of age
using standard morphological and histological analyses, as
well as 2D-targeted M-mode ECG, as previously described.11
LV function was assessed ex vivo in 12-week dysferlin/ and
WT mouse hearts using a buffer-perfused Langendorff appa-
ratus, as previously described.15
MHC-TRAF2LC/Dysferlin-Null Mice
MHC-TRAF2LC were outcrossed with dysferlin
/ mice to
produce F1 lines of MHC-TRAF2LC/dysferlin
/+ mice. F1
MHC-TRAF2LC/dysferlin
/+ mice were back-crossed with
dysferlin/ mice to generate MHC-TRAF2LC/dysferlin
/
mice or with 129 mice to generate WT/dysferlin+/+ control
mice. F2 lines of mice were used for all experiments.
For all studies reported herein, we used 12- to 14-week-old
male mice. Animals were housed under standard environ-
mental conditions and fed standard chow and tap water ad
libitum. All experiments were approved by the Institutional
Animal Care and Use Committees at the Baylor College of
Medicine and Washington University School of Medicine and
DOI: 10.1161/JAHA.113.000662 Journal of the American Heart Association 2















 at Washington University on March 4, 2014http://jaha.ahajournals.org/Downloaded from 
were conducted in accord with the guidelines of the Baylor
College of Medicine and Washington University School of
Medicine Animal Care and Research Advisory Committee and
the rules governing animal use, as published by the National
Institutes of Health (NIH; Bethesda, MD).
I/R Injury
Hearts from MHC-TRAF2DN, MHC-TRAF2LC, dysferlin
/, and
MHC-TRAF2LC/dysferlin
/ mice and their respective LM
and/or WT controls were isolated and perfused in the
Langendorff mode, as previously described.11 In brief, isolated
hearts were perfused at a constant pressure of 70 mm Hg
with modiﬁed Krebs-Henseleit buffer containing (in mmol) 118
NaCl, 24 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.2 CaCl2,
10 glucose, and 2 pyruvate, equilibrated with 95% O2-5% CO2
to yield a pH of 7.4 (37°C). A hand-made balloon was inserted
into the LV and connected to a pressure transducer (ML844;
ADInstruments, Colorado Springs, CO). The balloon was
inﬂated with water to adjust LV end-diastolic pressure (LVEDP)
at 5 to 10 mm Hg. All hearts were paced at 420 bpm with
pacing electrodes placed on the right atrium. After a 20-minute
stabilization period, hearts were subjected to no-ﬂow ischemia
(t=0 minutes) for 30 minutes, followed by reperfusion
(t=30 minutes) for up to 60 minutes (t=90 minutes). Func-
tional data were recorded at 1 kHz on a data acquisition
system (PowerLab; ADInstruments). LV developed pressure
(LVDP) was calculated as the difference between peak systolic
pressure and LVEDP, and the resulting LV functional recovery
data are expressed as the percentage of LVDP at baseline.
Assessment of Cardiac Myocyte Injury After I/R
Injury
To assess the effects of I/R injury on cardiac myocyte injury in
MHC-TRAF2DN, MHC-TRAF2LC, dysferlin
/, MHC-TRAF2LC/
dysferlin/, and WT control hearts, we assessed CK release
in the efﬂuent 30 minutes after reperfusion, as previously
described.11 Data are expressed as units per gram of cardiac
tissue. Because triphenyltetrazolium chloride staining may
underestimate the true extent of tissue injury within the ﬁrst
3 hours of cardiac injury,16 we used Evans blue dye uptake to
assess the degree of myocardial tissue injury after I/R injury,
as previously described.11 Brieﬂy, Evans blue dye crosses into
cells with permeable membranes and accumulates in myoﬁ-
brils, where it emits red autoﬂuorescence when examined
using ﬂuorescence microscopy. Fluorescence microscopy
(9200) was performed using a ﬁlter set with an excitation of
510 to 560 nm and an emission of 590 nm in order to assess
the amount of Evans blue dye uptake in the myocardium at
baseline and after I/R injury. Hearts were examined at the
level of the papillary muscle, using a total of 30 microscopic
ﬁelds per heart. Data are expressed as the percent area of the
myocardium with red ﬂuorescence.
Transcriptional Proﬁling in MHC-TRAF2LC and
MHC-TRAF2DN Hearts
Total RNA was extracted from hearts of MHC-TRAF2LC, MHC-
TRAF2DN, and LM control mice using TRIzol reagent (Invitro-
gen, Carlsbad, CA), according to the manufacturer’s instruc-
tions. Gene expression analysis was performed using the
Sentrix BeadChip and BeadStation system from Illumina, Inc
(San Diego, CA). RNA was further processed and hybridized to
a Mouse Ref-6.1.1 BeadChip array (Illumina). The mouse Ref-6
BeadChips contain sequences representing 46 000 curated
genes and expressed sequence tags (ESTs). After scanning
the probe array, the resulting image was analyzed using
BeadStudio software (Illumina). Samples were normalized
using a cubic spline procedure.
Differentially expressed genes between MHC-TRAF2LC and
MHC-TRAF2DN and LM controls were determined using an
ANOVA test with contrasts using Partek GS (Partek, St. Louis,
MO) using an unadjusted P value <0.05 and a fold change of
1.2 or greater. Agglomerative hierarchical clustering (combi-
nation of two rows/columns or clusters at each step of the
procedure) was also performed using Partek GS. Euclidean
distance was used to measure dissimilarity (the distance
between two rows or columns), and average linkage (the
average distance between all pairs of objects in two different
clusters) was used as the measure of distance between two
clusters. An analysis of gene expression in relation to cellular
components was performed using the Database for Annotation
Visualization and Integrated Discovery (http://david.abcc.n-
cifcrf.gov/),17 according to the classiﬁcation of cellular
components assigned by the Gene Ontology (GO) Consortium.
Dysferlin mRNA and Protein Expression in MHC-
TRAF2LC and MHC-TRAF2DN Hearts
Dysferlin mRNA levels were determined in 12-week hearts from
MHC-TRAF2LC, MHC-TRAF2DN, and LM control mice by real-
time quantitative polymerase chain reaction (RT-qPCR), using
an ABI 7500 Fast Real-Time quantitative PCR System (Applied
Biosystems, Foster City, CA). Two micrograms of total RNA was
reverse transcribed into cDNA using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). cDNAs were
amplied for 18S rRNA (Part No.: 4333760F) and dysferlin
(Assay ID No.: Mm00458042_m1) using the TaqMan gene
expression assay (Applied Biosystems), and the ﬁnal results
represent the fold change relative to LM controls using the
DDCt method with normalization to 18s expression.
Dysferlin protein levels were determined in membrane
preparations obtained from 12-week-old MHC-TRAF2LC, MHC-
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TRAF2DN, and LM control mice. Brieﬂy, LV tissue was
homogenized in isotonic sucrose buffer containing (in
mmol/L): 20.0 Tris-HCl, 250.0 sucrose, 1 Na3VO4, 2.0 MgCl2,
2.0 EDTA, 0.5 EGTA, 2.0 phenylmathanesulfonyl ﬂuoride, and
1.0 dithiothreitol and 0.02% (vol/vol) protease inhibitor
cocktail (pH 7.4). Homogenates were centrifuged at
100 000g for 60 minutes at 4°C to separate the particulate
fraction from the cytosolic fraction, and the resulting pellet
was resonicated in sucrose buffer containing 0.1% Triton X-
100 and centrifuged at 100 000g for 30 minutes at 4°C.
Equivalent amounts (50 lg) of supernatant protein were
separated on a 10% SDS-PAGE and transferred to nitrocellu-
lose membranes. Western blot analysis was performed using
rabbit anti-dysferlin (1:1000; Epitomics, Burlingame, CA),
followed by a peroxidase-labeled secondary antibody
(1:3000; Cell Signaling). Antigen-antibody complexes were
visualized by enhanced chemiluminescence (ECL; Amersham
Pharmacia Biotech, Piscataway, NJ). Membranes were incu-
bated at 70°C for 10 minutes in stripping buffer and then
reprobed for rabbit anti-calsequestrin (1:1000; Abcam, Cam-
bridge, MA). Original ﬁlms were exposed to ECL (HyperﬁlmTM,
ECLTM; Amersham Pharmacia Biotech), and band density was
determined (in arbitrary units) using the software, ImageJ
(NIH). Dysferlin protein levels were normalized by calseques-
trin levels to account for any potential loading differences.
NF-jB-Induced Activation of Dysferlin Gene
Expression
Previous studies from this laboratory have suggested that TNF-
TRAF2-mediated activation of NF-jB is responsible for provok-
ing cytoprotective responses in the heart after I/R injury.11 To
determine whether NF-jB was involved in upregulation of
dysferlin in MHC-TRAF2LC mouse hearts, we performed a
chromatin immunoprecipitation (ChIP) assay using the EZ-ChIP
Assay Kit (Millipore, Temecula, CA), following the manufac-
turer’s instructions. Brieﬂy, mouse hearts were minced and
incubated in PBS containing 1% formaldehyde at room temper-
ature for 10 minutes to cross-link proteins to DNA. Cross-
linking was stopped by adding 2.5 mol/L glycine to a ﬁnal
concentration of 0.125 mol/L. Tissue was then washed twice
in cold PBS, homogenized in 2 mL PBS containing Protease
Inhibitor Cocktail II, pelleted, and resuspended in 1 mL SDS
lysis buffer containing Protease Inhibitor Cocktail II. Chromatin
was sonicated to shear cross-linked DNA to200 to 1000 bp in
length. Sheared chromatin was precleared with Protein G
Agarose for 1 hour at 4°Cwith rotation. After pelleting agarose,
1% volume of each sample was removed to use as input. The
remaining chromatin was immunoprecipitated with antibodies
against NF-jB family members (RelB: sc-226, Santa Cruz; p50:
ab7971, Abcam; p65: No. 8242, Cell Signaling; p52: ab7972,
Abcam) or control antibodies overnight at 4°C with rotation.
Protein G Agarose was then added to protein/DNA complexes
at 4°C for 1 hour. Agarose was pelleted and washed sequen-
tially with low-salt buffer, high-salt buffer, LiCl wash buffer, and
Tris-EDTA buffer. Protein/DNA cross-links were reversed by
incubating samples at 65°C overnight. Chromatin was then
digested with RNase at 37°C for 30 minutes and with
proteinase K at 45°C for 2 hours. DNA was puriﬁed with spin
ﬁlters provided with the kit. PCR was performed with 4 lL of
immunoprecipitated DNA using the following primers: forward,
50CATATAAGCCTGTGCCCTCATAAGAAC 30; reverse, 50GGATGC
TGTAGATAGACGACTGAGAA30. Primers were chosen based on





To determine whether I/R injury resulted in differential
localization of dysferlin in cardiac myocytes from MHC-TRAFLC
mouse hearts, compared to LM controls, we performed
immunohistochemical (IHC) staining at baseline and after
60 minutes of I/R injury. Brieﬂy, hearts were subjected to the
I/R protocol exactly as described above and were then
perfuse ﬁxed with Z-ﬁx (Anatech, Battle Creek, MI). Antigen
retrieval was performed by placing slides in retrieval buffer
(180 lmol/L citric acid, 820 lmol/L sodium citrate) and
heating in a microwave 39 for 4 minutes. Tissue was then
permeabilized using 19 TBS/0.1% Triton X-100 for 20 min-
utes at room temperature. After permeabilization, tissue was
blocked in a buffer containing 109 blocking reagent (Roche,
Indianapolis, IN), 9 mL FCS, and 27 maleate buffer
(100 mmol/L maleic acid, 150 mmol/L NaCl; pH 7.5) for
30 minutes at room temperature. A primary rabbit anti-
dysferlin monoclonal antibody (Romeo; Epitomics, Burlin-
game, CA) was applied overnight at 4°C (1:50 dilution in
blocking buffer). Slides were washed with 19 TBS/0.1%
Tween 39 5 minutes each and labeled with a red ﬂuores-
cence-conjugated anti-rabbit secondary antibody (Alexa Fluor
647; Life Technologies, Carlsbad, CA) for 1 hour at room
temperature (1:500 dilution in blocking buffer). Slides were
washed with TBS/0.1% Tween, mounted with Vectashield
containing 4’,6-diamidino-2-phenylindole (DAPI; Vector Labo-
ratories, Burlingame, CA), and imaged using a Zeiss confocal
(LSM 700 Laser Scanning Confocal; Carl Zeiss GmbH, Jena,
Germany) microscope using DAPI and Alexa Fluor 647 ﬁlters.
Statistical Analysis
Data are expressed as meanSEM. Two-way repeated-
measures ANOVA was used to test for differences in percent
LVDP between groups as a function of time after I/R injury
between groups. Post-hoc ANOVA testing was performed,
where appropriate, using Fisher’s least signiﬁcant difference
DOI: 10.1161/JAHA.113.000662 Journal of the American Heart Association 4















 at Washington University on March 4, 2014http://jaha.ahajournals.org/Downloaded from 
test.18 CK release, the area of the myocardium (%) with Evans
blue uptake after I/R injury, dysferlin mRNA and protein
levels, and heart weight/body weight ratios were examined
using a nonpaired t test. All data were tested for normality
before performing parametric testing. Signiﬁcant differences
were said to exist at P<0.05.
Results
Generation and Characterization of Tg and
Knockout Mice
MHC-TRAF2DN Tg mice
We obtained ﬁve founder lines of mice, harboring 1, 10, 15,
25, and 30 copies of the cardiac-restricted TRAF2DN trans-
gene. For the present study, we selected the MHC-TRAFDN
line harboring 30 copies of the transgene (MHC-TRAF2DN).
MHC-TRAF2DN mice were born with the expected Mendelian
frequency and developed normally. MHC-TRAF2DN mice
lacked a cardiac phenotype at 12 weeks of age, as assessed
by gross morphology and hematoxylin and eosin (H&E)
staining (Figure 1A), as well as by assessment of heart
weight/body weight ratio (Figure 1B), and 2D ECG assess-
ment of LV structure (Figure 2A through 2C). Further
characterization of 12-week-old mice showed no differences
in LV function in MHC-TRAF2DN, compared with LM controls,
when assessed in vivo by 2D ECG or ex vivo by buffer-
perfursed Langendorff apparatus (Figure 2D through 2G). To
further characterize MHC-TRAF2DN mice, we examined NF-jB
and JNK activity in 12-week-old LM and MHC-TRAF2DN mice.
As expected, neither NF-jB nor JNK were activated in na€ıve
MHC-TRAF2DN mouse hearts. EMSAs from hearts of mice with
targeted overexpression of TRAF2, which were used as
positive controls, had activation of NF-jB, as we have
reported previously.19
Figure 1. Characterization of transgenic mice expressing dominant negative TRAF2 (MHC-TRAF2DN),
compared to littermate (LM) control mice. A, Representative photographs of 12-week MHC-TRAF2DN
transgenic and LM control hearts, hematoxylin and eosin–strained cross-sections at the level of the
papillary muscle, and representative hematoxylin and eosin–stained cross-sections at the level of the
papillary muscles (9400). B, Heart weight/body weight ratio (n=6/group). C, Left panel: Electromobility
shift assay (EMSA) of NF-jB activation in nuclear extracts from LM, MHC-TRAF2LC (positive control), MHC-
TRAF2DN, and lipopolysaccharide (LPS)-stimulated hearts (20 mg/kg intraperitoneally for 1 hour).
Speciﬁcity of DNA-protein-binding nuclear extracts was determined using a 209 molar excess of the
respective unlabeled oligonucleotide. D, JNK activation assay in LM and TRAF2DN hearts (12 weeks) at
baseline and after I/R injury. BW indicates body weight; HW, heart weight; I/R, ischemia-reperfusion; JNK,
c-Jun N-terminal kinase; MHC, myosin heavy chain; NF-jB, nuclear factor kappa B; TRAF2, tumor necrosis
factor receptor-associated factor 2.
DOI: 10.1161/JAHA.113.000662 Journal of the American Heart Association 5















 at Washington University on March 4, 2014http://jaha.ahajournals.org/Downloaded from 
Effects of Cardiac-Restricted Overexpression of
Dominant Negative TRAF2 After I/R Injury
To determine the effects of loss of TRAF2-mediated signaling
after I/R injury, we subjected MHC-TRAF2DN mice to
30 minutes of no-ﬂow ischemia, followed by 60 minutes of
reperfusion. The salient ﬁnding shown by Figure 3A is that
hearts from MHC-TRAF2DN mice had signiﬁcantly worse LV
functional recovery at 10 to 60 minutes (P<0.05/time point)
after reperfusion, when compared to the LM control mice. To
determine whether the decreased functional recovery of
MHC-TRAF2DN mice was the result of increased myocyte
injury, we measured CK release and Evans blue dye uptake
30 minutes after reperfusion. As shown in Figure 3B, there
was a signiﬁcant (P<0.05) 1.4-fold increase in CK release after
I/R injury in MHC-TRAF2DN hearts, when compared to LM
control hearts. Consistent with these ﬁndings, there was a
signiﬁcant (P<0.05) increase in Evans blue dye uptake in
MHC-TRAF2DN mouse hearts, as depicted by the representa-
tive ﬂuorescence photomicrographs shown in Figure 3C and
the group data summarized in Figure 3D. In contrast, hearts
from MHC-TRAF2LC mice that were subjected to I/R injury
demonstrated signiﬁcantly improved LV functional recovery
10 to 60 minutes (P<0.05/time) after IR injury, compared to
LM controls, consistent with our earlier observations.11
Viewed together, these results suggest that low levels of
myocardial TRAF2 are sufﬁcient to protect cardiac myocytes
against I/R injury, whereas loss of TRAF2-mediated signaling
in cardiac myocytes leads to increased cardiac myocyte injury
and decreased functional recovery after I/R injury.
Transcriptional Proﬁling in MHC-TRAF2LC and
MHC-TRAF2DN Hearts
To explore the potential mechanisms responsible for the
cytoprotective effects of TRAF2 in the adult heart, we
performed transcriptional proﬁling in 12-week-old na€ıve LM,
MHC-TRAF2LC, and MHC-TRAF2DN hearts. Transcriptional
proﬁling revealed that there were 1059 upregulated genes
and 1199 downregulated genes in MHC-TRAF2LC hearts, in
comparison to LM controls, whereas MHC-TRAF2DN hearts
had 965 upregulated genes and 1089 downregulated genes,
in comparison to LM controls (Figure 4A and 4B). Agglomer-
ative hierarchical clustering of these transcriptional proﬁles
showed that gene expression proﬁles in the MHC-TRAF2LC
and MHC-TRAF2DN mouse hearts clustered differently than
those in LM control hearts (Figure 5), suggesting that gain
and loss of TRAF2 signaling in the heart results in discordant
Figure 2. LV structure and function in MHC-TRAF2DN mice. 2D-targeted echocardiography was used in
12-week MHC-TRAF2DN transgenic and littermate (LM) control mice to determine (A) LV end-diastolic
dimension (LVEDD), (B) LV posterior wall diameter (LVPWd), (C) ratio of LV radius to LV wall thickness (r/h),
and (D) percent LV fractional shortening (% FS) (n=5 control group; n=6 transgenic mice). Buffer-perfused
Langendorff apparatus was used to determine (E) percent LV developed pressure (LVDP), (F) LV +dP/dt,
and (G) LV dP/dt in 12-week MHC-TRAF2DN transgenic and LM hearts (n=6/group). LV indicates left
ventricle; TRAF2, tumor necrosis factor receptor-associated factor 2.
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changes in gene expression relative to WT levels of TRAF2
signaling. Moreover, gene expression proﬁles of MHC-
TRAF2DN hearts clustered with LM control hearts. Based
upon the functional studies shown in Figure 3, which
suggested that gain and loss of function of TRAF2 signaling
led, respectively, to improved and worsened responses to I/R
injury, as well as the transcriptional proﬁling studies, which
suggested that MHC-TRAF2DN and the MHC-TRAF2LC mouse
hearts had distinct gene proﬁles, we focused our search for
potential candidate cytoprotective genes on those genes
whose expression level (relative to LM) was discordant
(opposite) in MHC-TRAF2DN and in the MHC-TRAF2LC mouse
hearts. Figure 4 shows that there were 94 discordant genes
that were upregulated in MHC-TRAF2LC mice and downreg-
ulated in MHC-TRAF2DN mice (referred to as “Up/Down”;
Figure 4A), and there were 110 discordant genes that were
downregulated in MHC-TRAF2LC mice and upregulated in
MHC-TRAF2DN mice (referred to as “Down/Up”; Figure 4B).
Of the 94 discordant genes identiﬁed in the Up/Down group,
there were 25 expressed sequence tags (ESTs) and 69 known
genes. Of the 110 discordant genes in the Down/Up group,
there were 31 ESTs and 79 known genes (see Table 1). We
then performed a GO analysis of cellular components on the
148 genes identiﬁed in the Up/Down and Down/Up groups.
As shown in Figure 4C, the cellular components that were
enriched (greatest to least) included cytoplasm
(P=0.0479104), mitochondrion (P=0.0259104), plasma
membrane (P=0.047), cytoskeleton (P=0.052), endosome
(P=0.014), and nucleus (P=0.09). Given that our results
implicated TRAF2 signaling with preservation of membrane
integrity after I/R injury (Figure 3C and 3D), as well as
previous in vitro studies from this laboratory, which demon-
strated that TNFR1- and TNFR2-mediated signaling preserved
sarcolemmal integrity after hypoxia reoxygenation injury,5 we
focused our search on genes in the plasma membrane gene
cluster. Table 2 depicts those discordantly regulated genes in
MHC-TRAF2DN and MHC-TRAF2LC mouse hearts that were
identiﬁed in the plasma membrane gene cluster. An expanded
Figure 3. Effects of I/R injury on transgenic mice expressing low levels of TRAF2 (MHC-TRAF2LC) or
dominant negative TRAF2 (MHC-TRAF2DN) and their respective littermate (LM) controls. A, Percent of left
ventricular developed pressure after I/R injury (n=6/group). B, CK release in the efﬂuent 30 minutes after
I/R injury in MHC-TRAF2DN and LM controls (n=7/group). C, Representative images of Evans blue dye
uptake. Red coloration indicates uptake of Evans blue dye into necrotic/permeable cardiac myocytes. D,
Group data for Evans blue uptake (n=7/group). *P<0.05, compared to LM controls. CK indicates creatine
kinase; I/R, ischemia-reperfusion; LVDP, left ventricle developed pressure; TRAF2, tumor necrosis factor
receptor-associated factor 2.
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version of this table that includes gene function (neXProt
[http://www.nextprot.org/db/]) and the GO biological pro-
cesses for each gene (http://www.geneontology.org) is
presented in Table 3. Inspection of Table 3 reveals that there
were clusters of genes involved in the cytoskeleton/integrins
(ENAH, ITGB5, VASP, RALB, ITGB1, DST, and SYNC), ion
channels (KCNH2, KCNB1), energetics (ATP1B1), cell death
(FKBP8, RHOB, and MFGE8), membrane trafﬁcking (DYS,
MSN, RAB11A, and RAB3A), and cell signaling (PPP1R9B,
PLXND, EPS15, CAMK2N1, ATF6B, ASAH2, and CISH). Of
these potential candidate genes, dysferlin was of particular
interest because of its role in maintaining sarcolemmal
integrity through exocytotic membrane “patch” repair.20 We
therefore focused on the potential role of dysferlin in TRAF2-
mediated cytoprotection.
To conﬁrm results with respect to the dysferlin gene array
transcriptional proﬁling studies, we performed RT-qPCR and
Western blot analysis in hearts of LM, MHC-TRAF2DN, and
MHC-TRAF2LC mouse hearts. As shown in Figure 6A, mRNA
levels of dysferlin were signiﬁcantly increased (P<0.05) in
MHC-TRAF2LC hearts, compared to LM controls. Although
there was a decrease in dysferlin mRNA in MHC-TRAF2DN
hearts, when compared to LM controls, this change was not
signiﬁcantly statistically (P=0.09). Importantly, Western blot
analysis demonstrated that membrane protein levels of
dysferlin were 1.8-fold upregulated (P<0.0001) in MHC-
TRAF2LC hearts and downregulated 0.7-fold (P<0.05) in
MHC-TRAF2DN hearts, compared to respective LM controls
(Figure 6B). Accordingly, we focused subsequent studies on
Figure 4. Transcriptional proﬁles of MHC-TRAF2LC and MHC-TRAF2DN hearts. A, Venn diagram of
signiﬁcantly (P<0.05) upregulated transcripts in MHC-TRAF2LC (1086) and downregulated transcripts in
MHC-TRAF2DN (833), compared to LM controls (Up/Down). B, Venn diagram of signiﬁcantly (P<0.05)
downregulated transcripts in MHC-TRAF2LC (1103) and upregulated in MHC-TRAF2DN (844), compared to
LM controls (Down/Up). C, Gene ontology cellular component analysis of the discordant genes (Up/Down
and Down/Up transcripts). LM indicates littermate; TRAF2, tumor necrosis factor receptor-associated
factor 2.
Figure 5. Transcriptional proﬁling of MHC-TRAF2LC and MHC-
TRAF2DN hearts. Hierarchical clustering of signiﬁcant changes in
gene expression in 12-week MHC-TRAF2LC and MHC-TRAF2DN
control mice, relative to LM controls. LM indicates littermate;
TRAF2, tumor necrosis factor receptor-associated factor 2.
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Table 1. Discordant Genes in TRAF2LC and TRAF2DN Mice









TSC22D4 TSC22 domain family, member 4 7.03E-05 4.41 3.95E-02 1.18
CCND2 Cyclin D2 1.56E-03 1.94 2.58E-02 1.28
PSMD8 Proteasome (prosome, macropain) 26S subunit,
non-ATPase, 8
9.57E-03 1.72 1.86E-02 1.53
CKB Creatine kinase, brain 1.11E-03 1.67 8.51E-04 1.76
SYNPO2L Synaptopodin 2-like 3.21E-03 1.67 4.73E-02 1.21
MLLT11 Myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila); translocated to, 11
1.12E-03 1.61 1.42E-02 1.22
PLXNB2 Plexin B2 3.01E-04 1.60 8.14E-03 1.16
ACTA2 Actin, alpha 2, smooth muscle, aorta 2.43E-02 1.51 4.68E-03 2.10
VASP Vasodilator-stimulated phosphoprotein 8.38E-03 1.50 4.49E-02 1.24
SERPINH1 Serpin peptidase inhibitor, clade H (heat shock protein
47), member 1, (collagen binding protein 1)
9.25E-03 1.49 4.94E-02 1.24
MASP1 Mannan-binding lectin serine peptidase 1 (C4/C2
activating component of Ra-reactive factor)
2.29E-03 1.44 4.52E-03 1.33
STXBP1 Syntaxin-binding protein 1 2.37E-02 1.43 3.86E-02 1.35
PPP1R9B Protein phosphatase 1, regulatory (inhibitor) subunit 9B 2.66E-03 1.37 2.16E-02 1.16
TMEM63C Transmembrane protein 63C 4.21E-03 1.37 3.14E-02 1.16
NAT11 N-acetyltransferase 11 1.59E-03 1.36 7.99E-03 1.19
PLXND1 Plexin D1 2.43E-02 1.36 4.15E-02 1.29
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 2.76E-02 1.36 2.58E-02 1.37
IGFBP5 Insulin-like growth factor binding protein 5 2.44E-02 1.36 2.86E-02 1.33
ITGB5 Integrin, beta 5 1.45E-03 1.33 7.93E-04 1.42
EPS15 Epidermal growth factor receptor pathway substrate 15 1.01E-02 1.31 5.12E-03 1.41
MAST4 Microtubule-associated serine/threonine kinase family
member 4
1.37E-02 1.30 1.34E-02 1.30
CAMK2N1 Calcium/calmodulin-dependent protein kinase II
inhibitor 1
4.60E-02 1.29 3.41E-02 1.34
HSP90AB1 Heat shock protein 90 kDa alpha (cytosolic), class B
member 1
3.57E-02 1.29 3.94E-02 1.27
SOAT1 Sterol O-acyltransferase (acyl-coenzyme A: cholesterol
acyltransferase) 1
3.36E-03 1.28 2.65E-02 1.12
ENAH Enabled homolog (Drosophila) 8.93E-03 1.27 2.06E-03 1.49
MIF Macrophage migration inhibitory factor (glycosylation-
inhibiting factor)
8.68E-03 1.27 1.94E-02 1.20
KBTBD10 Kelch repeat and BTB (POZ) domain-containing 10 1.44E-03 1.26 3.46E-03 1.19
RHOB Ras homolog gene family, member B 2.37E-02 1.26 1.49E-03 1.84
RNF145 Ring finger protein 145 7.85E-03 1.25 4.94E-02 1.12
CAND1 Cullin-associated and neddylation-dissociated 1 1.30E-02 1.24 4.44E-02 1.14
TUBB2C Tubulin, beta 2C 3.16E-03 1.24 3.51E-03 1.23
SQSTM1 Sequestosome 1 3.63E-02 1.23 6.86E-03 1.46
HSPB8 Heat shock 22 kDa protein 8 1.78E-02 1.23 8.29E-03 1.31
RBPMS2 RNA-binding protein with multiple splicing 2 1.91E-02 1.23 3.94E-02 1.17
Continued
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Table 1. Continued
Gene Symbol Gene Name P Value Fold Change P Value Fold Change
ATF6 Activating transcription factor 6 3.49E-02 1.22 3.94E-02 1.21
NOL8 Nucleolar protein 8 4.74E-05 1.21 6.60E-03 1.04
SAMD9L Sterile alpha motif domain-containing 9-like 3.83E-03 1.20 7.88E-04 1.38
PPP1R12A Protein phosphatase 1, regulatory (inhibitor) subunit
12A
2.00E-02 1.20 6.90E-03 1.31
ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12)
4.56E-02 1.20 4.37E-03 1.53
SLC11A2 Solute carrier family 11 (proton-coupled divalent metal
ion transporters), member 2
3.83E-02 1.20 4.15E-02 1.19
PPM1E Protein phosphatase 1E (PP2C domain containing) 1.64E-02 1.20 3.72E-02 1.14
DYNC1LI2 Dynein, cytoplasmic 1, light intermediate chain 2 3.11E-02 1.20 1.42E-02 1.27
ITPR1 Inositol 1,4,5-triphosphate receptor, type 1 2.56E-02 1.19 2.21E-02 1.21
NDOR1 NADPH-dependent diflavin oxidoreductase 1 1.17E-02 1.19 3.33E-03 1.32
DST Dystonin 3.82E-02 1.19 1.78E-02 1.25
CDC16 Cell division cycle 16 homolog (Saccharomyces
cerevisiae)
3.91E-02 1.18 1.04E-02 1.32
WDR36 WD repeat domain 36 1.04E-02 1.18 3.08E-02 1.12
ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10 2.02E-02 1.18 4.15E-02 1.13
LRRC51 Leucine-rich repeat containing 51 1.06E-02 1.17 4.27E-02 1.10
PABPC4 Poly(A)-binding protein, cytoplasmic 4 (inducible form) 5.98E-03 1.17 1.08E-02 1.14
DNAJC18 DnaJ (Hsp40) homolog, subfamily C, member 18 3.05E-02 1.17 2.13E-02 1.20
MFGE8 Milk fat globule-EGF factor 8 protein 1.95E-02 1.17 4.36E-02 1.12
IRF6 Interferon-regulatory factor 6 3.01E-02 1.15 1.47E-02 1.20
ARL5A ADP-ribosylation factor-like 5A 1.07E-04 1.15 2.01E-03 1.05
LUZP1 Leucine zipper protein 1 3.85E-02 1.15 1.42E-02 1.22
RAB11A RAB11A, member RAS oncogene family 2.33E-02 1.14 7.66E-03 1.21
THOC2 THO complex 2 8.06E-03 1.13 1.12E-02 1.12
FBXW2 F-box and WD repeat domain-containing 2 2.22E-02 1.13 6.08E-03 1.21
ASAH2 N-acylsphingosine amidohydrolase (nonlysosomal
ceramidase) 2
4.35E-03 1.12 1.42E-02 1.08
MYCBP C-myc-binding protein 1.25E-02 1.12 5.37E-03 1.16
AGPS Alkylglycerone phosphate synthase 4.74E-02 1.11 2.64E-02 1.14
RCC1 Regulator of chromosome condensation 1 4.75E-02 1.10 2.32E-02 1.14
ZNF202 Zinc finger protein 202 1.72E-02 1.10 7.47E-03 1.14
HEXA Hexosaminidase A (alpha polypeptide) 8.52E-03 1.10 1.03E-02 1.09
SKIV2L2 Superkiller viralicidic activity 2-like 2 (S. cerevisiae) 1.39E-02 1.09 2.86E-02 1.07
DYSF Dysferlin, limb girdle muscular dystrophy 2B (autosomal
recessive)
1.66E-02 1.09 2.67E-02 1.07
MSN Moesin 2.68E-02 1.07 3.24E-02 1.06
GALT Galactose-1-phosphate uridylyltransferase 4.03E-02 1.05 3.10E-03 1.14
ARL6 ADP-ribosylation factor-like 6 4.90E-03 1.05 8.02E-03 1.04
Down and up LC-TRAF2 vs WT LC-TRAF2 vs WT DN-TRAF2 vs WT DN-TRAF2 vs WT
EFNB3 Ephrin B3 3.69E-05 2.27 3.81E-03 1.19
ABHD1 Abhydrolase domain-containing 1 3.31E-04 2.03 4.88E-03 1.33
Continued
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Table 1. Continued
Gene Symbol Gene Name P Value Fold Change P Value Fold Change
MDH1 Malate dehydrogenase 1, NAD (soluble) 8.96E-03 1.82 2.88E-02 1.48
MAOB Monoamine oxidase B 1.21E-04 1.72 1.68E-02 1.11
GSTK1 Glutathione S-transferase kappa 1 4.46E-04 1.71 3.02E-02 1.13
DNASE2A Deoxyribonuclease II alpha 5.52E-05 1.66 2.27E-02 1.07
RHD Rh blood group, D antigen 4.76E-04 1.50 4.62E-04 1.50
KDM5D Lysine (K)-specific demethylase 5D 2.79E-04 1.43 6.58E-03 1.13
ATP5E ATP synthase, H+ transporting, mitochondrial F1
complex, epsilon subunit
5.91E-03 1.40 1.55E-02 1.27
LGALS4 Lectin, galactose binding, soluble 4 1.12E-03 1.38 9.53E-03 1.17
NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex,
10
4.33E-02 1.38 2.27E-02 1.51
DBT Dihydrolipoamide branched chain transacylase E2 4.12E-03 1.34 3.35E-02 1.15
C8B Complement component 8, beta subunit 2.21E-02 1.34 9.23E-03 1.49
CD80 CD80 antigen 5.90E-03 1.34 1.13E-02 1.26
ATP5F1 ATP synthase, H+ transporting, mitochondrial F0
complex, subunit b, isoform 1
2.32E-03 1.33 5.28E-03 1.24
CHKB Choline kinase beta 1.81E-03 1.32 2.29E-02 1.12
FIGF C-fos-induced growth factor 2.03E-03 1.31 2.38E-02 1.12
APPL2 Adaptor protein, phosphotyrosine interaction, PH
domain and leucine zipper-containing 2
2.16E-03 1.31 8.06E-03 1.19
KCNH2 Potassium voltage-gated channel, subfamily H (eag-
related), member 2
7.73E-03 1.29 6.20E-03 1.32
MRPL30 Mitochondrial ribosomal protein L30 1.70E-02 1.29 2.23E-02 1.26
SEMA5B Sema domain, 7 thrombospondin repeats (type 1 and
type 1-like), transmembrane domain (TM) and short
cytoplasmic domain, (semaphorin) 5B
2.48E-03 1.29 4.89E-03 1.22
ASB11 Ankyrin repeat and SOCS box-containing protein 11 1.27E-03 1.29 4.41E-02 1.07
GMNN Geminin 6.20E-03 1.28 1.92E-02 1.18
MRPS28 Mitochondrial ribosomal protein S28 2.15E-02 1.27 2.86E-02 1.24
GOLGA2 Golgi autoantigen, golgin subfamily a, 2 8.62E-03 1.25 1.80E-03 1.47
DCAKD Dephospho-CoA kinase domain containing 3.50E-02 1.25 3.58E-02 1.24
SYNC Syncoilin 2.32E-02 1.25 4.54E-02 1.18
PXMP2 Peroxisomal membrane protein 2 1.37E-04 1.24 9.15E-03 1.27
PLCXD3 Phosphatidylinositol-specific phospholipase C, X
domain containing 3
5.06E-03 1.24 1.39E-02 1.16
CCNG1 Cyclin G1 7.62E-04 1.24 1.25E-04 1.49
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 2
3.48E-02 1.24 3.27E-02 1.24
TCEA3 Transcription elongation factor A (SII), 3 2.42E-02 1.23 3.58E-02 1.20
MRPL47 Mitochondrial ribosomal protein L47 1.35E-02 1.23 1.42E-03 1.58
PDYN Prodynorphin 1.63E-03 1.23 5.16E-03 1.15
ACADL Acyl-coenzyme A dehydrogenase, long-chain 2.62E-02 1.23 2.62E-03 1.60
OLFR29-PS1 Olfactory receptor 29, pseudogene 1 8.34E-03 1.23 2.52E-02 1.15
ICT1 Immature colon carcinoma transcript 1 7.11E-03 1.22 1.48E-02 1.17
CSDA Cold shock domain protein A 2.78E-04 1.22 5.70E-04 1.17
Continued
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Table 1. Continued
Gene Symbol Gene Name P Value Fold Change P Value Fold Change
CISH Cytokine-inducible SH2-containing protein 1.73E-02 1.22 6.49E-03 1.33
NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 6 (B14)
4.11E-02 1.21 6.94E-03 1.44
PLCB2 Phospholipase C, beta 2 4.18E-05 1.21 1.93E-02 1.02
XLR3A X-linked lymphocyte-regulated 3A 1.13E-02 1.20 2.55E-02 1.15
KCNB1 Potassium voltage-gated channel, Shab-related
subfamily, member 1
8.84E-03 1.20 9.40E-03 1.20
ACIN1 Apoptotic chromatin condensation inducer 1 2.55E-02 1.19 6.94E-03 1.32
NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6 2.42E-03 1.18 2.00E-02 1.08
UBE2G1 Ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C.
elegans)
4.22E-02 1.18 3.65E-02 1.19
IL20RA Interleukin-20 receptor, alpha 2.84E-02 1.18 4.50E-02 1.15
FXC1 Fractured callus expressed transcript 1 2.15E-03 1.17 8.43E-03 1.11
DLD Dihydrolipoamide dehydrogenase 2.97E-02 1.17 4.52E-03 1.35
NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex,
5
4.94E-03 1.16 2.00E-02 1.10
TRPT1 TRNA phosphotransferase 1 4.20E-02 1.16 1.88E-02 1.22
OLFR1352 Olfactory receptor 1352 7.35E-03 1.15 3.58E-02 1.08
FERT2 Fer (fms/fps-related) protein kinase, testis
specific 2
1.71E-03 1.15 4.94E-03 1.10
C6 Complement component 6 6.16E-03 1.14 2.65E-02 1.08
DUS1L Dihydrouridine synthase 1-like (S cerevisiae) 9.65E-03 1.14 3.56E-03 1.20
OLFR1335 Olfactory receptor 1335 1.21E-03 1.13 4.37E-02 1.04
TMEM126B Transmembrane protein 126B 4.24E-02 1.13 2.20E-03 1.44
MRPS21 Mitochondrial ribosomal protein S21 2.64E-02 1.13 3.65E-02 1.11
CNP 20,30-cyclic nucleotide 30 phosphodiesterase 4.53E-02 1.12 5.52E-03 1.28
UBR4 Ubiquitin protein ligase E3 component n-recognin 4 4.91E-02 1.12 1.87E-02 1.18
CDC26 Cell division cycle 26 1.17E-02 1.12 8.80E-03 1.13
PARP2 Poly (ADP-ribose) polymerase family, member 2 3.56E-02 1.11 6.40E-03 1.22
COQ10A Coenzyme Q10 homolog A (yeast) 1.71E-02 1.11 1.43E-03 1.28
ZFP655 Zinc finger protein 655 3.09E-02 1.11 2.50E-02 1.12
RNF113A2 Ring finger protein 113A2 1.09E-02 1.11 3.44E-03 1.16
SPINLW1 Serine protease inhibitor-like, with Kunitz and WAP
domains 1 (eppin)
2.07E-02 1.10 1.96E-03 1.25
SULT3A1 Sulfotransferase family 3A, member 1 1.99E-03 1.10 4.19E-02 1.03
RNASEH2A Ribonuclease H2, large subunit 4.89E-02 1.10 4.22E-02 1.11
RBM33 RNA-binding motif protein 33 4.26E-02 1.10 7.29E-03 1.20
IKBKAP Inhibitor of kappa light polypeptide enhancer in B cells,
kinase complex-associated protein
4.41E-02 1.09 1.29E-02 1.15
TRAF4 TNF receptor-associated factor 4 1.17E-02 1.09 4.31E-03 1.13
PPP2R2D Protein phosphatase 2, regulatory subunit B, delta
isoform
4.29E-02 1.09 1.08E-02 1.16
MRGPRB4 MAS-related GPR, member B4 3.12E-03 1.08 3.01E-03 1.08
DPP6 Dipeptidylpeptidase 6 1.90E-02 1.08 4.64E-03 1.14
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Table 1. Continued
Gene Symbol Gene Name P Value Fold Change P Value Fold Change
MRPL1 Mitochondrial ribosomal protein L1 1.41E-02 1.07 3.37E-04 1.30
ARSA Arylsulfatase A 4.48E-02 1.07 2.77E-02 1.09
LEF1 Lymphoid enhancer-binding factor 1 2.25E-02 1.06 1.34E-02 1.07
JMJD2C Jumonji domain-containing 2C 1.03E-02 1.05 2.08E-02 1.04
PCNA Proliferating cell nuclear antigen 3.57E-02 1.05 7.19E-04 1.23
LM indicates littermate; WT, wild type.
Table 2. Changes in Gene Expression Identiﬁed in Gene Ontology of Cellular Components
Symbol Gene Name
Fold Change Fold Change
LC-TRAF2 Versus WT DN-TRAF2 Versus WT
Plasma membrane: up/down
VASP Vasodilator-stimulated phosphoprotein 1.50 1.24
PPP1R9B Protein phosphatase 1, regulatory (inhibitor) subunit 9B 1.37 1.16
PLXND1 Plexin D1 1.36 1.29
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 1.36 1.37
ITGB5 Integrin, beta 5 1.33 1.42
EPS15 Epidermal growth factor receptor pathway substrate 15 1.31 1.41
CAMK2N1 Calcium/calmodulin-dependent protein kinase II inhibitor 1 1.29 1.34
ENAH Enabled homolog (Drosophila) 1.27 1.49
RHOB Ras homolog gene family, member B 1.26 1.84
ATF6B Activating transcription factor 6 beta 1.22 1.21
ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 1.20 1.53
SLC11A2 Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 1.20 1.19
DST Dystonin 1.19 1.25
MFGE8 Milk fat globule-EGF factor 8 protein 1.17 1.12
RAB11A RAB11A, member RAS oncogene family 1.14 1.21
ASAH2 N-acylsphingosine amidohydrolase (nonlysosomal ceramidase) 2 1.12 1.08
DYSF Dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive) 1.09 1.07
MSN Moesin 1.07 1.06
Plasma membrane: down/up
MAOB Monoamine oxidase B 1.72 1.11
C8B Complement component 8, beta polypeptide 1.34 1.49
CD80 CD80 molecule 1.34 1.26
KCNH2 Potassium voltage-gated channel, subfamily H (eag-related), member 2 1.29 1.32
SYNC Syncoilin, intermediate filament protein 1.25 1.18
CSDA Cold shock domain protein A 1.22 1.17
CISH Cytokine-inducible SH2-containing protein 1.22 1.33
KCNB1 Potassium voltage-gated channel, Shab-related subfamily, member 1 1.20 1.20
ARSA Arylsulfatase A 1.07 1.09
Bold indicates candidate gene selected for study.
TRAF2 indicates tumor necrosis factor receptor-associated factor 2; WT, wild type.
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Table 3. Expanded Gene Lists in the Plasma Membrane Compartment





Ena/VASP proteins are actin-associated proteins
involved in a range of processes dependent on
cytoskeleton remodeling and cell polarity, such as
axon guidance, lamellipodial and filopodial dynamics,
platelet activation, and cell migration. VASP
promotes actin filament elongation. It protects the
barbed end of growing actin filaments against
capping and increases the rate of actin
polymerization in the presence of capping protein.
VASP stimulates actin filament elongation by
promoting the transfer of profilin-bound actin
monomers onto the barbed end of growing actin
filaments; plays a role in actin-based mobility of
Listeria monocytogenes in host cells; regulates actin
dynamics in platelets; and plays an important role in
regulating platelet aggregation.
Actin polymerization or depolymerization








Acts as a scaffold protein in multiple signaling
pathways; modulates excitatory synaptic
transmission and dendritic spine morphology; binds
to actin filaments (F-actin) and shows cross-linking
activity; binds along the sides of the F-actin; may
play an important role in linking the actin
cytoskeleton to the plasma membrane at the
synaptic junction; believed to target protein
phosphatase 1/PP1 to dendritic spines, which are
rich in F-actin, and regulates its specificity toward
ion channels and other substrates, such as AMPA-
and NMDA-type glutamate receptors; plays a role in
regulation of G-protein-coupled receptor signaling,
including dopamine D2 receptors and alpha-
adrenergic receptors; binds to ADRA1B and RGS2
and mediates regulation of ADRA1B signaling; may
confer to Rac signaling specificity by binding to both
RacGEFs and Rac effector proteins; probably
regulates p70 S6 kinase activity by forming a
complex with TIAM1 (by similarity)
Cell cycle arrest (GO:0007050); cell
differentiation (GO:0030154); cell
migration (GO:0016477); cellular
response to morphine [GO:0071315];
filopodium assembly (GO:0046847);
negative regulation of cell growth
(GO:0030308); nervous system
development (GO:0007399); regulation of
cell proliferation (GO:0042127);





PLXND1 Plexin D1 Cell surface receptor for SEMA4A and for class 3
semaphorins, such as SEMA3A, SEMA3C, and
SEMA3E; plays an important role in cell-cell
signaling, and in regulating the migration of a wide
spectrum of cell types; regulates the migration of
thymocytes in the medulla; regulates endothelial cell
migration; plays an important role in ensuring the
specificity of synapse formation; required for normal
development of the heart and vasculature (by
similarity); mediates antiangiogenic signaling in
response to SEMA3E
Angiogenesis (GO:0001525); dichotomous
subdivision of terminal units involved in
salivary gland branching (GO:0060666);
endothelial cell migration (GO:0043542);
patterning of blood vessels
(GO:0001569); regulation of
angiogenesis (GO:0045765); regulation








This is the noncatalytic component of the active
enzyme, which catalyzes the hydrolysis of ATP
coupled with the exchange of Na(+) and K(+) ions
across the plasma membrane. The beta subunit
regulates, through assembly of alpha/beta
heterodimers, the number of sodium pumps
transported to the plasma membrane.
ATP biosynthetic process (GO:0006754);
response to hypoxia (GO:0001666);
transport (GO:0006810)
ITGB5 Integrin beta-5 Integrin alpha-V/beta-5 is a receptor for fibronectin. It
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Table 3. Continued







Involved in cell growth regulation; may be involved in
the regulation of mitogenic signals and control of cell
proliferation; involved in the internalization of ligand-
inducible receptors of the receptor tyrosine kinase
(RTK) type, in particular, EGFR; plays a role in the
assembly of clathrin-coated pits (by similarity)
Cell proliferation (GO:0008283); clathrin







Potent and specific inhibitor of CaM-kinase II (CAMK2) None listed
ENAH Enabled homolog Ena/VASP proteins are actin-associated proteins
involved in a range of processes dependent on
cytoskeleton remodeling and cell polarity, such as
axon guidance and lamellipodial and filopodial
dynamics in migrating cells.
Actin binding (GO:0003779); SH3 domain





Mediates apoptosis in neoplastically transformed cells
after DNA damage; not essential for development,
but affects cell adhesion and growth factor signaling
in transformed cells; plays a negative role in
tumorigenesis because deletion causes tumor
formation; involved in intracellular protein trafficking
of a number of proteins; targets PKN1 to endosomes
and is involved in trafficking of the EGF receptor from
late endosomes to lysosomes; also required for
stability and nuclear trafficking of AKT1/AKT, which
promotes endothelial cell survival during vascular
development; serves as a microtubule-dependent
signal that is required for the myosin contractile ring
formation during cell cycle cytokinesis; required for
genotoxic stress-induced cell death in breast cancer
cells.
Angiogenesis (GO:0001525); apoptotic
process (GO:0006915); cell adhesion
(GO:0007155); cell cycle cytokinesis
(GO:0033205); cellular response to
hydrogen peroxide (GO:0070301);
Cellular response to ionizing radiation
(GO:0071479); endosome to lysosome
transport (GO:0008333); GTP catabolic
process (GO:0006184); negative
regulation of cell cycle (GO:0045786);
positive regulation of angiogenesis
(GO:0045766); positive regulation of
apoptotic process (GO:0043065); protein
transport (GO:0015031); Rho protein
signal transduction (GO:0007266);





Transcriptional factor that acts in the unfolded protein
response (UPR) pathway by activating UPR target
genes induced during ER stress; binds DNA on the
50-CCAC[GA]-30 half of the ER stress response
element (ERSE) (50-CCAATN(9)CCAC[GA]-30) when
NF-Y is bound to ERSE
Regulation of transcription, DNA dependent





ITGB1 Integrin beta-1 Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/
beta-1, and alpha-11/beta-1 are receptors for
collagen. Integrins alpha-1/beta-1 and alpha-2/beta-
2 recognize the proline-hydroxylated sequence G-F-
P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-
3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/
beta-1, alpha-10/beta-1, alpha-11/beta-1, and
alpha-V/beta-1 are receptors for fibronectin. Integrin
alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1, and
alpha-7/beta-1 are receptors for lamimin. Integrin
alpha-9/beta-1 is a receptor for VCAM1, cytotactin,
and osteopontin. It recognizes the sequence A-E-I-D-
G-I-E-L in cytotactin. Integrin alpha-3/beta-1 is a
receptor for epiligrin, thrombospondin, and CSPG4.
Integrin alpha-V/beta-1 is a receptor for vitronectin.
B cell differentiation (GO:0030183);
calcium-independent cell-matrix
adhesion (GO:0007161); cardiac muscle
cell differentiation (GO:0055007); cell fate
specification (GO:0001708); cell
migration (GO:0016477); cell migration
involved in sprouting angiogenesis
(GO:0002042); cell-cell adhesion
mediated by integrin (GO:0033631); cell-
matrix adhesion (GO:0007160); cellular
defense response (GO:0006968); cellular
response to ionizing radiation
(GO:0071479); cellular response to
vitamin D (GO:0071305); G1/S transition
of mitotic cell cycle (GO:0000082); germ
cell migration (GO:0008354); homophilic
cell adhesion (GO:0007156); in utero
Continued
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Table 3. Continued







involved in female pregnancy
(GO:0060135); negative regulation of cell
projection organization (GO:0031345);
negative regulation of cell proliferation
(GO:0008285); negative regulation of
neuron differentiation (GO:0045665);
positive regulation of apoptotic process
(GO:0043065); positive regulation of cell
migration (GO:0030335); any process
that activates or increases the frequency,
rate, or extent of cell migration; positive
regulation of cell proliferation
(GO:0008284); positive regulation of cell-
substrate adhesion (GO:0010811);
positive regulation of endocytosis
(GO:0045807); positive regulation of
MAPK cascade (GO:0043410); positive
regulation of neuron differentiation
(GO:0045666); positive regulation of
neuron projection development
(GO:0010976); positive regulation of
peptidyl-tyrosine phosphorylation
(GO:0050731); protein transport within
lipid bilayer (GO:0032594); regulation of
cell cycle (GO:0051726); regulation of G-
protein-coupled receptor protein
signaling pathway (GO:0008277);
response to activity (GO:0014823);
response to drug (GO:0042493);
response to gonadotropin stimulus
(GO:0034698); response to transforming
growth factor beta stimulus
(GO:0071559); sarcomere organization
(GO:0045214); tight junction assembly
(GO:0070830); tissue homeostasis
(GO:0001894)







Important in metal transport, in particular, iron; can also
transport manganese, cobalt, cadmium, nickel,
vanadium, and lead; involved in apical iron uptake
into duodenal enterocytes; involved in iron transport
from acidified endosomes into the cytoplasm of
erythroid precursor cells; may play an important role
in hepatic iron accumulation and tissue iron
distribution
Activation of cysteine-type endopeptidase
activity involved in apoptotic process
(GO:0006919); cellular response to
oxidative stress (GO:0034599); transport
of cobalt, cadmium, copper, iron, lead,
nickel, vanadium, and zinc (GO:multiple




DST Dystonin Cytoskeletal linker protein; acts as an integrator of
intermediate filaments, actin, and microtubule
cytoskeleton networks; required for anchoring either
intermediate filaments to the actin cytoskeleton in
neural and muscle cells or keratin-containing
intermediate filaments to hemidesmosomes in
Axonogenesis (GO:0007409); cell adhesion
(GO:0007155); cell cycle arrest
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Table 3. Continued
Symbol Gene Name Function GO Biological Process
epithelial cells; the proteins may self-aggregate to





of cell polarity (GO:0030011);
microtubule cytoskeleton organization
(GO:0000226); regulation of microtubule
polymerization or depolymerization
(GO:0031110); response to wounding
(GO:0009611); retrograde axon cargo
transport (GO:0008090)
MFGE8 Lactadherin Plays an important role in the maintenance of intestinal
epithelial homeostasis and the promotion of mucosal
healing; promotes VEGF-dependent
neovascularization (by similarity); contributes to
phagocytic removal of apoptotic cells in many
tissues; specific ligand for the alpha-v/beta-3 and
alpha-v/beta-5 receptors; also binds to
phosphatidylserine-enriched cell surfaces in a
receptor-independent manner; zona pellucida-
binding protein, which may play a role in gamete
interaction; binds specifically to rotavirus and inhibits
its replication





positive regulation of apoptotic cell
clearance (GO:2000427); positive
regulation of cell proliferation






Regulates endocytic recycling; may exert its functions
by interacting with multiple effector proteins in
different complexes; acts as a major regulator of
membrane delivery during cytokinesis; together with
MYO5B and RAB8A, participates in epithelial cell
polarization; together with RAB3IP, RAB8A, the
exocyst complex, PARD3, PRKCI, ANXA2, CDC42,
and DNMBP, promotes transcytosis of PODXL to the
apical membrane initiation sites (AMIS), apical
surface formation, and lumenogenesis (by similarity);
together with MYO5B, participates in CFTR trafficking
to the plasma membrane and TF (transferrin)
recycling in nonpolarized cells; required in a complex
with MYO5B and RAB11FIP2 for the transport of
NPC1L1 to the plasma membrane; participates in the
sorting and basolateral transport of CDH1 from the
Golgi apparatus to the plasma membrane; regulates
the recycling of FCGRT (receptor of Fc region of
monomeric IgG) to basolateral membranes (by
similarity)
Cell cycle (GO:0007049) cytokinesis
(GO:0000910); GTP catabolic process
(GO:0006184); neuron projection
development (GO:0031175); plasma
membrane to endosome transport
(GO:0048227); protein localization in
plasma membrane (GO:0072659);
regulation of long-term neuronal synaptic
plasticity (GO:0048169); regulation of










Hydrolyzes the sphingolipid ceramide into sphingosine
and free fatty acid at an optimal pH of 6.5 to 8.5;
acts as a key regulator of sphingolipid signaling
metabolites by generating sphingosine at the cell
surface; acts as a repressor of apoptosis both by
reducing C16-ceramide, thereby preventing
ceramide-induced apoptosis, and generating
sphingosine, a precursor of the antiapoptotic factor,
sphingosine 1-phosphate; probably involved in the
digestion of dietary sphingolipids in intestine by
acting as a key enzyme for the catabolism of dietary
sphingolipids and regulating the levels of bioactive
sphingolipid metabolites in the intestinal tract
Apoptotic process (GO:0006915); ceramide
metabolic process (GO:0006672); signal
transduction (GO:0007165)
DYSF Dysferlin Key calcium ion sensor involved in the Ca(2+)-triggered
synaptic key calcium ion sensor involved in Ca(2+)-
None identified
Continued
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Table 3. Continued
Symbol Gene Name Function GO Biological Process
triggered synaptic vesicle-plasma membrane fusion;
plays a role in the sarcolemma repair mechanism of
both skeletal muscle and cardiomyocytes that
permits rapid resealing of membranes disrupted by
mechanical stress
MSN Moesin Probably involved in connections of major cytoskeletal
structures to the plasma membrane; may inhibit











Catalyzes the oxidative deamination of biogenic and
xenobiotic amines and has important functions in the metabolism
of neuroactive and vasoactive amines in
the central nervous system and peripheral tissues;
MAOB preferentially degrades benzylamine and
phenylethylamine.
Negative regulation of serotonin secretion
(GO:0014063); positive regulation of
dopamine metabolic process
(GO:0045964); response to aluminum ion
(GO:0010044); response to
corticosterone stimulus (GO:0051412);
response to drug (GO:0042493);
response to ethanol (GO:0045471);
response to lipopolysaccharide
(GO:0032496); response to selenium ion





Constituent of the membrane attack complex (MAC)
that plays a key role in the innate and adaptive
immune response by forming pores in the plasma










Involved in the costimulatory signal essential for T-
lymphocyte activation; T-cell proliferation and
cytokine production is induced by the binding of





regulation of alpha-beta T-cell
proliferation (GO:0046641); positive
regulation of the granulocyte
macrophage colony-stimulating factor
biosynthetic process (GO:0045425);
positive regulation of the interleukin-2
biosynthetic process (GO:0045086);
Positive regulation of peptidyl-tyrosine
phosphorylation (GO:0050731); positive
regulation of signal transduction
(GO:0009967); positive regulation of T-
helper 1 cell differentiation









Pore-forming (alpha) subunit of voltage-gated inwardly
rectifying potassium channel; channel properties are
modulated by cAMP and subunit assembly; mediates
the rapidly activating component of the delayed
rectifying potassium current in heart (IKr)
Blood circulation (GO:0008015); muscle
contraction (GO:0006936); potassium ion
transport (GO:0006813); protein
heterooligomerization (GO:0051291);
regulation of heart contraction
(GO:0008016); regulation of membrane
Continued
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dysferlin as a potential candidate gene for the cytoprotective
effects of TRAF2.
NF-jB-Induced Activation of Dysferlin Gene
Expression
Previous studies from this laboratory have suggested that
TNF/TRAF2-mediated activation of NF-jB is responsible for
provoking cytoprotective responses in the heart after I/R
injury.11 Previously, we have reported that both RelB and p52
were upregulated in hearts of MHC-TRAF2LC mice, when
compared to LM controls.19 To determine whether compo-
nents of noncanonical NF-jB signaling were responsible for
the observed increased in dysferlin expression in MHC-
TRAF2LC mouse hearts, we performed a ChIP assay. As shown
in Figure 7, there was a signiﬁcant 2-fold increase in RelB
binding to the dysferlin (variant 1) promoter in MHC-TRAF2LC
hearts, when compared to WT hearts, which was accompanied
by signiﬁcant binding of p50 and p52, which are potential
binding partners for RelB. These experiments suggest that
TRAF2-mediated activation of NF-KB contributed to increased
dysferlin expression observed in MHC-TRAF2LC hearts.
Table 3. Continued
Symbol Gene Name Function GO Biological Process
potential (GO:0042391); regulation of
transcription, DNA dependent
(GO:0006355)
SYNC Syncoilin Intermediate filament Intermediate filament-based process
(GO:0045103)
CSDA Cold shock domain
protein A
Binds to the GM-CSF promoter; seems to act as a
repressor; binds also to full-length mRNA and to
short RNA sequences containing the consensus site
50-UCCAUCA-30; may have a role in translation
repression
Fertilization (GO:0009566); in utero
embryonic development (GO:0001701);
male gonad development (GO:0008584);
negative regulation of apoptotic process
(GO:0043066); negative regulation of
skeletal muscle tissue development
(GO:0048642); negative regulation of
transcription from RNA polymerase II
promoter (GO:0000122); organ
regeneration (GO:0031100); positive
regulation of organ growth
(GO:0046622); regulation of
transcription, DNA dependent








SOCS family proteins form part of a classical negative
feedback system that regulates cytokine signal
transduction. CIS is involved in the negative
regulation of cytokines that signal through the JAK-
STAT5 pathway, such as erythropoietin, prolactin,
and interleukin-3 (IL-3) receptor. Inhibits STAT5
transactivation by suppressing its tyrosine
phosphorylation; may be a substrate-recognition
component of an SCF-like ECS (Elongin BC-CUL2/5-
SOCS-box protein) E3 ubiquitin-protein ligase
complex, which mediates the ubiquitination and
subsequent proteasomal degradation of target
proteins (by similarity).
Intracellular signal transduction
(GO:0035556); negative regulation of
signal transduction (GO:0009968);
protein ubiquitination (GO:0016567);






Mediates the voltage-dependent potassium ion
permeability of excitable membranes; channels open
or close in response to the voltage difference across
the membrane, letting potassium ions pass in accord
with their electrochemical gradient
Protein homooligomerization (GO:0051260)
ARSA Arylsulfatase A Hydrolyzes cerebroside sulfate None identified
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Characterization of the Dysferlin-Null Mice
Phenotypic Characterization of Dysferlin-Null
(Dysferlin/) Mice
In order to explore the role of dysferlin as a potential mediator
of the cytoprotective effects of TRAF2, we ﬁrst characterized
the phenotype of the dysferlin-null (dysferlin/) mice
employed in these studies. Figure 8A shows that 12-week-
old dysferlin/ mice had no obvious LV phenotype, as
assessed by gross morphology and H&E staining. There was,
however, a small, but signiﬁcant, increase in the heart
weight/body weight ratio in dysferlin/ mice, when com-
pared to WT controls (Figure 8B). 2D-targeted M-mode echo
disclosed no signiﬁcant differences in LV fractional shortening
(Figure 8C) or LVDP (Figure 8D), LV +dP/dt (Figure 8E) and
LV dP/dt (Figure 8F), or LV dimensions (Figure 8G through
8I) between dysferlin/ knockout mice, compared to WT
controls.
I/R Injury
Although previous studies in dysferlin-null mice have failed to
demonstrate a role for dysferlin in reducing infarct size after
acute coronary ligation in vivo,14 the role of dysferlin after I/R
injury (wherein the mechanisms of cell injury are different) is
not known. Accordingly, we subjected dysferlin/ mouse
hearts to 30 minutes of global ischemia, followed by
60 minutes of reperfusion. The salient ﬁnding shown by
Figure 9A is that LV functional recovery after I/R injury was
signiﬁcantly (P<0.001 by ANOVA) worse in dysferlin-null
hearts, when compared to WT. Differences in LVDP were
evident 20 minutes after reperfusion and remained signiﬁ-
cantly worse than WT controls 60 minutes after reperfusion
(P<0.05/time). Importantly, both myocardial CK release
(Figure 9B) and degree of uptake of Evans blue dye (Figure 9C
and 9D) were signiﬁcantly increased (P<0.05 for both) in
hearts of I/R-injured dysferlin-null mice, when compared to
WT controls. These results are consistent with the thesis that
dysferlin-mediated membrane repair is important for main-
Figure 6. Expression levels of dysferlin mRNA and protein levels in MHC-TRAF2LC, MHC-TRAF2DN, and
littermate (LM) control) mice. A, mRNA levels in na€ıve 12-week-old MHC-TRAF2LC and MHC-TRAF2DN,
relative to respective LM control hearts (n=6/group). B, Representative Western blot of dysferlin protein
levels in na€ıve 12-week-old MHC-TRAF2LC and MHC-TRAF2DN and group data for dysferlin protein (relative
to calsequestrin) in MHC-TRAF2LC and MHC-TRAF2DN hearts (n=8/group). *P<0.05, compared to the
respective LM control. TRAF2 indicates tumor necrosis factor receptor-associated factor 2.
Figure 7. NF-jB chromatin immunprecipitation (ChIP). RelB,
p50, p65, and p52 antibodies were used for ChIP on mouse heart
chromatin. Presence of NF-jB family members at a jB site in the
dysferlin promoter was detected by PCR and expressed as fold
change relative to WT controls (n=3). LM indicates littermate; NF-
jB, nuclear factor kappa B; PCR, polymerase chain reaction;
TRAF2, tumor necrosis factor receptor-associated factor 2; WT,
wild type.
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taining membrane integrity and LV functional recovery after
I/R injury.
Effects of Dysferlin on TRAF2-Mediated
Cytoprotection After I/R Injury
To determine whether the cytoprotective effects of TRAF2
were mediated, at least in part, through dysferlin, we
generated MHC-TRAF2LC/dysferlin
/ mice and subjected
these hearts to I/R injury. The important ﬁnding shown by
Figure 10A is that the cytoprotective effects of TRAF2 were
attenuated signiﬁcantly in a dysferlin-null background. As
shown, functional recovery in MHC-TRAF2LC/dysferlin
/
mice was signiﬁcantly less than MHC-TRAF2LC mice at 10 to
60 minutes (P<0.05/time point) after reperfusion. Further-
more, there was a signiﬁcant increase in myocardial CK
release (Figure 10B) and degree of uptake of Evans blue dye
(Figure 10C and 10D; P<0.05 for both) in hearts of I/R-
Figure 8. Characterization of dysferlin-null (dysferlin/) mice. Dysferlin/ and wild-type (WT) control
mice were 12 weeks of age. A, Representative photographs of dysferlin/ and WT control hearts;
hematoxylin and eosin–stained cross-sections at the level of the papillary muscle and representative
hematoxylin and eosin–stained cross sections at the level of the papillary muscles (9400). B, Heart weight/
body weight ratio (n=6/group) of dysferlin/ hearts and WT controls. C, Percent LV fractional shortening
(% FS) in 12-week-old dysferlin/ hearts (n=9) and WT controls (n=6). D, Percent LV developed pressure (%
LVDP) ex vivo (n=6 hearts/group). E and F, LV +dP/dt and LV dP/dt ex vivo (n=9/group). G, LV end-
diastolic dimension (LVEDD), (H) LV posterior wall diameter (LVPWd), and (I) ratio of LV radius to LV wall
thickness (r/h). *P<0.05, compared to the respective WT control. BW indicates body weight; HW, heart
weight; LV, left ventricle.
DOI: 10.1161/JAHA.113.000662 Journal of the American Heart Association 21















 at Washington University on March 4, 2014http://jaha.ahajournals.org/Downloaded from 
injured MHC-TRAF2LC/dysferlin
/ mice, when compared to
MHC-TRAF2LC mice. A second important ﬁnding shown in
Figure 10A is that the overall degree of functional recovery in
the MHC-TRAF2LC/dysferlin
/ mice was signiﬁcantly greater
than WT control mice (P<0.001), suggesting that the
cytoprotective effects of TRAF2 are not exclusively mediated
through dysferlin.
To determine whether I/R injury resulted in differential
localization of dysferlin in cardiac myocytes from MHC-TRAFLC
mouse hearts, compared to LM controls, we performed IHC
staining at baseline in na€ıve hearts and 60 minutes after I/R
injury. As shown by the representative photomicrographs in
Figure 11, dysferlin was not immunodetectable in cardiac
myocytes from LM controls or MHC-TRAFLC mouse hearts. It
contrast, after I/R injury, dysferlin was weakly detectable in the
cytoplasm of scattered cardiac myocytes from control hearts,
whereas dysferlin immunostaining was easily detectable at the
intercalated disks and diffusely throughout the cytoplasm of
cardiac myocytes from MHC-TRAFLC mouse hearts, suggesting
that TRAF2 signaling resulted in increased dysferlin trafﬁcking
to the membrane of MHC-TRAFLC mouse hearts.
Discussion
The results of this study, in which we employed both gain- and
loss-of-function approaches to delineate the mechanism(s) for
the cytoprotective effects of TRAF2, suggest that TRAF2-
mediated upregulation of dysferlin is responsible, at least in
part, for the cytoprotective effects of TRAF2 after I/R injury.
As shown in Figure 3A, Tg mouse lines with cardiac-restricted
overexpression of low levels of TRAF2 (MHC-TRAF2LC) had
improved LV functional recovery after I/R injury, relative to
LM controls, whereas mice with cardiac-restricted overex-
pression of MHC-TRAF2DN had decreased LV functional
recovery after I/R injury. Decreased functional recovery in
MHC-TRAF2DN mice was accompanied by increased CK
release (Figure 3B) and Evans blue dye uptake (Figure 3C
and 3D), consistent with increased membrane permeability.
Improved functional recovery in MHC-TRAF2LC mice is
associated with decreased CK release and decreased Evans
blue dye uptake, consistent with enhanced membrane
stability.11 To delineate the mechanisms for the cytoprotec-
tive effects of TRAF2, we performed transcriptional proﬁling in
Figure 9. Effects of ischemia-reperfusion (I/R) injury in dysferlin-null (dysferlin/) mice and wild-type
(WT) control mice. Dysferlin/ and WT control mice were 12 weeks of age. A, Percent LV developed
pressure after I/R injury (n=6 hearts/group). B, Creatine kinase (CK) release in the efﬂuent at baseline and
30 minutes after I/R injury (n=6 hearts/group). C, Representative images of Evans blue dye uptake. D,
Group data for Evans blue dye uptake at baseline and 30 minutes after I/R injury (n=6 hearts/group).
*P<0.05, compared to WT controls. LV indicates left ventricle; LVDP, LV developed pressure.
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MHC-TRAF2LC and MHC-TRAF2DN mouse hearts. Using this
unbiased strategy, we identiﬁed a calcium-triggered exocy-
totic membrane repair protein, termed dysferlin, as a potential
candidate cytoprotective gene downstream from TRAF2-
mediated signaling (Figure 4 and Table 2). Importantly, dys-
ferlin mRNA and protein were signiﬁcantly upregulated in
MHC-TRAF2LC mice, whereas dysferlin protein was signiﬁ-
cantly downregulated in MHC-TRAF2DN mice (Figure 6).
Moreover, dysferlin was immunolocalized to the intercalated
disks and diffusely throughout the cytoplasm of cardiac
myocytes from MHC-TRAF2LC mouse hearts after I/R injury,
whereas it was weakly detectable in the cytoplasm of WT
control hearts (Figure 11). Consistent with our earlier obser-
vations, which have implicated an important role for NF-jB
signaling in terms of mediating the cytoprotective effects of
the TNF-TRAF2-signaling pathway,11 the ChIP assay identiﬁed
RelB, p50, and p52 binding in the promoter region of the
dysferlin gene (Figure 7). Characterization of dysferlin-null
mice revealed that they had decreased functional LV recovery,
increased CK release, and increased Evans blue dye uptake
after I/R injury (Figure 9), thus phenocopying the response to
I/R injury observed in MHC-TRAF2DN mice. Finally, breeding
MHC-TRAF2LC mice onto a dysferlin-null background (MHC-
TRAF2LC/dysferlin
/) resulted in increased tissue injury,
increased Evans Blue dye uptake, and decreased functional
recovery, when compared to MHC-TRAF2LC mice (Figure 10),
suggesting that dysferlin mediates, at least in part, the
cytoprotective effects of TRAF2. Importantly, functional
recovery in MHC-TRAF2LC/dysferlin
/ mice after I/R injury
was still signiﬁcantly greater than observed in WT controls
(Figure 10A), suggesting that cytoprotective effects of TRAF2
are not mediated exclusively through dysferlin. Indeed, TRAF2
mediates mitophagy through an E3 ligase-dependent mech-
anism in the adult heart.21 Although speculative, these results
suggest that the cytoprotective effects of TRAF2 may relate to
clearance of mitochondria that are damaged after I/R injury.
Dysferlin-Mediated Membrane Repair in the
Mammalian Heart
Given that maintenance of plasma membrane integrity is
required for cell viability, it is not surprising that cells have
Figure 10. Effects of ischemia-reperfusion (I/R) injury in MHC-TRAF2LC, MHC-TRAF2LC/dysferlin/, and
littermate (LM) controls. All studies were performed in 12-week-old mice (see Methods for breeding
strategy). A, Percent LV developed pressure after I/R injury (n=6 to 7 hearts/group). B, Creatine kinase
(CK) release in the efﬂuent at baseline and 30 minutes after I/R injury (n=6 hearts/group). C,
Representative images of Evans blue dye uptake. D, Group data for Evans blue dye uptake at baseline and
30 minutes after I/R injury (n=3 control hearts; n=4 dysferlin/ hearts). *P<0.05 and compared to WT
controls; +P<0.05, compared to MHC-TRAF2LC/dysferlin
/). LM indicates littermate; LV, left ventricle;
LVDP, LV developed pressure; TRAF2, tumor necrosis factor receptor-associated factor 2; WT, wild type.
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evolved a variety of different “emergency repair” mechanisms
to facilitate plasma membrane resealing under physiologic
and pathophysiologic conditions. This is particularly important
for cells residing in mechanically stressful environments, such
as cardiac and/or skeletal myocytes.20,22–24 In mammalian
cells, plasma membranes reseal spontaneously if the lesion is
small (<1 lmol/L). If the membrane lesion is large (>1 lmol/
L), nucleated cells use an active membrane repair process
that is based on Ca2+-triggered active trafﬁcking of cytoplas-
mic vesicles to the site of membrane damage with
subsequent fusion of vesicles with the plasma membrane
(exocytosis), thereby creating a “patch” of new membrane
across the gap in the plasma membrane. The process of
active membrane fusion during exocytosis requires several
membrane proteins, including SNARE proteins,25 synaptotag-
mins,26 and a recently described muscle-speciﬁc TRIM
protein, MG53, that is important in sarcolemmal repair in
ischemic preconditioning.27
Recently, a family of proteins termed “ferlins” has been
shown to play an important role in membrane repair by
facilitating Ca2+-mediated trafﬁcking of vesicles to the site of
membrane injury. The ferlin family consists of four different
highly conserved genes that encode dysferlin, myoferlin,
otoferlin, and Fer1L4 (reviewed previously25). Dysferlin is a
273 kDa type II transmembrane protein that is enriched in
skeletal and cardiac muscle.20 Mutations in dysferlin lead to
three distinct muscular dystrophies (“dysferlinopathies”):
limb-girdle muscular dystrophy type 2B;28 Miyoshi myopa-
thy;28 and distal myopathy with anterior tibialis onset.
Although onset of dilated cardiomyopathy is extremely rare
in dysferlinopathies, 50% of patients develop mild structural
(increased myocardial ﬁbrosis) and functional (diastolic dys-
function) cardiac abnormalities.29,30 These ﬁndings are con-
sistent with experimental studies that have shown that aging
dysferlin-deﬁcient mice develop progressive myocardial ﬁbro-
sis by 10 to 12 months of age, suggesting an important role
for membrane repair mechanisms in aging hearts.14,31
Relevant to the present study, dysferlin deﬁciency has been
implicated in the development of a dilated cardiomyopathic
phenotype after adrenergic and/ormechanical stress.14,30 Han
et al. demonstrated increased cardiac myocyte membrane
permeability (increased Evans blue dye uptake) and progressive
LV dysfunction in exercising dysferlin-null mice. Although these
researchers did not demonstrate a role for dysferlin in reducing
Figure 11. Dysferlin immuohistochemical staining in littermate controls and MHC-TRAFLC mouse hearts.
In na€ıve hearts, dysferlin was not immunodetectable in cardiac myocytes from littermate controls (A) or
MHC-TRAFLC mouse hearts (B). In contrast, after I/R injury, dysferlin was weakly detectable in the
cytoplasm of scattered cardiac myocytes from control hearts (B and C). As shown by arrows, dysferlin
immunostaining was easily detectable at the intercalated disks (E) and diffusely throughout the cytoplasm
(F) of cardiac myocytes from MHC-TRAFLC mouse hearts, suggesting that TRAF2 signaling resulted in
increased dysferlin trafﬁcking to the membrane of the MHC-TRAFLC mouse heart. I/R indicates ischemia
reperfusion; TRAF2, tumor necrosis factor receptor-associated factor 2.
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infarct size after acute coronary ligation, they did not examine
the role of dysferlin in I/R injury, wherein the mechanisms of
cell injury are different. Our results are in agreement with these
earlier studies that have demonstrated an important role for
dysferlin-mediated membrane repair during mechanical
stress14 and extend these observations by demonstrating the
importance of membrane resealing as a critical component of
the cytoprotective effects of inﬂammatory signaling after I/R
injury. These results are also concordant with our earlier in vitro
observations, wherein we demonstrated that TNF-mediated
signaling through TNFR1 or TNFR2 preserved sarcolemmal
membrane integrity (calcium inﬂux and lactic dehyrogenase
release) in isolated cardiac myocytes that were subjected to
hypoxia reoxygenation injury.5
Although the present study did not delineate the mecha-
nism(s) for the cytoprotective role of dysferlin during I/R
injury, it bears emphasis that the exact mechanisms respon-
sible for dysferlin-mediated membrane repair are incompletely
understood.32 Moreover, these studies were conducted ex
vivo, which excludes the effects of inﬁltrating inﬂammatory
cells that could also affect innate immune signaling, Accord-
ingly, it will be important, in future studies, to further
delineate the interacting protein partners for dysferlin in
MHC-TRAF2LC mice, as well as extend these observations to
studies in vivo Finally, we cannot exclude the formal
possibility that the deleterious effects observed in MHC-
TRAF2DN mice after I/R injury were nonspeciﬁc, and were
secondary to high levels of expression of the transgene, as
has been reported for inert proteins that have been overex-
pressed in the heart.
Conclusions
The results of this study demonstrate, for the ﬁrst time, that
TRAF2-mediated signaling confers cytoprotection in the heart,
at least in part, through upregulation of dysferlin, a calcium-
triggered exocytotic membrane repair protein. Although the
innate immune system has been implicated in maintaining
“barrier function” in the skin, gastrointestinal system, and
trachea in vertebrate species,33,34 these observations have
focused predominately on activation of the adaptive immune
system by the innate immune system in response to
disruption of the epithelial barrier. Our results extend this
conceptual paradigm and suggest that one of the important
functions of innate immune activation in the heart in response
to tissue injury is preservation and maintenance of the
physical barrier between the extra- and intracellular environ-
ment through enhanced and/or facilitated sarcolemmal
repair, thereby preventing calcium-induced activation of cell
death machinery, loss of cytosolic constituents vital to cell
function, as well as preserving the electrochemical gradient
across the sarcolemma that is required for membrane
excitability and myocyte contraction. Consistent with this
thesis, both gain- and loss-of-function studies have shown
that TNF and TNF receptors are required for preservation of
epidermal barrier function in mice.35 This point of view is also
consistent with the “danger” model of immunity, which
proposes that healthy tissue induces tolerance (eg, precon-
ditioning), whereas unhealthy tissue stimulates the adaptive
immune system, which would be activated by release of
damage-associated molecular patterns.36 Given that loss of
dysferlin-mediated membrane repair attenuated, but did not
abrogate, the cytoprotective effects of TRAF2-mediated
signaling, it will be important, in subsequent studies, to
determine whether additional plasma membrane proteins that
were identiﬁed by our screening strategy contribute to
maintaining sarcolemmal repair after I/R injury.
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